Ascil Biopharm was formed in 2012, our first business unit is internal projects of control release formulations and Medical device projects, and the second business unit is R&D and CDMO services for non-GMP or GMP operations with manufacturing capabilities for early phase clinical batches. We are a clinical-stage Drug Delivery System company with a proven track record of developing injectable solutions and more than 50 individual patent families with hundreds of DDS formulations and device patents. We have acquired R&D centers and obtained the GMP certification. We can support partners on slow-release formulations, ultra-high concentrations, and viscous injectable solutions.
Focus Areas